Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

European Institute of Oncology

Status and phase

Active, not recruiting

Phase 2

Conditions

Lobular Carcinoma in Situ

CDH1 Gene Mutation

BRCA Mutation

RAD51C Gene Mutation

PALB2 Gene Mutation

RAD51D Gene Mutation

CHEK2 Gene Mutation

ATM Gene Mutation

Ductal Carcinoma in Situ

Treatments

Other: Intermittent caloric restriction

Drug: Tamoxifen 10 mg Tablet

Behavioral: Step counter Device

Study type

Interventional

Funder types

Other

NETWORK

Identifiers

NCT06033092

2023-503994-39-00 (Other Identifier)

UID 3751

Details and patient eligibility

About

Circulating levels of Sex Hormone Binding Globulin (SHBG) are significantly associated with a decreased risk of breast cancer.

The main aim of this clinical trial is to verify whether Low Dose Tamoxifen (LDT) increases circulating levels of SHBG more than lifestyle intervention (LI) with or without intermittent caloric restriction (ICR) after 6 months in women at increased risk of breast cancer (i.e., healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes: BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or with > 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models or with a recently resected intraepithelial neoplasia of the breast (IEN).

The secondary aims are:

to verify whether ICR significantly modulates primary and secondary endpoints such as Homeostasis Model Assessment (HOMA) index, immune and inflammatory markers, lipid profile, Adiponectin/Leptin (A/L) ratio, quality of life (QoL), Body mass index (BMI), fat body composition, safety and toxicity;
to verify whether LDT significantly modulates secondary endpoints, such as HOMA-index, immune and inflammatory markers, lipid profile, A/L ratio, QoL, BMI, fat body composition, safety and toxicity;
to investigate differences in microbiome composition by arms and the effect of changes in microbiome on QoL taking into account circulating biomarkers, cytokines, immune modulators, and inflammatory proteins in serum;
to investigate MD (Mammographic Breast Density) changes by LDT vs. LI, with or without ICR. This aim will be performed in a subgroup of participants (not all the participants will undergo mammography due to younger age).

Full description

Italian, multicenter, phase II, biomarker trial. A total of 200 women aged 18-70 years will be randomly assigned (1:1:1:1) to one of the four intervention arms Arm 1: Low dose Tamoxifen (LDT) i.e. 10 mg every other day; Arm 2: Low dose Tamoxifen (LDT) + Intermittent Caloric Restriction (ICR); Arm 3: Lifestyle intervention (LI) using a step counter; Arm 4: Lifestyle intervention (LI) using a step counter + Intermittent Caloric Restriction (ICR).

Participants will be stratified by center and by disease status (high risk vs. previous IEN) and intervention will last six months for all arms.

Enrollment

200 estimated patients

Sex

Female

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Women between 18 and 70 years old;
Healthy participants carriers of a germline pathogenic/likely pathogenetic variant in at least one of the following genes BRCA1, BRCA2, PALB2, ATM, CHEK2, CDH1, RAD51C or RAD51D, or

> 5% breast cancer risk at 10 years, using the Tyrer Cuzick or the Breast Cancer Surveillance Consortium Risk models, or

with previous diagnosis of intraepithelial neoplasia (surgery for ADH, LCIS, ER positive DCIS) within the last 3 years;
Ability to understand and the willingness to sign a written informed consent document;
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1;

5a. For high-risk strata: A negative mammogram or any radiological image based on age and center protocol screening within 6 months before baseline visit;

5b. For IEN Strata: A negative mammogram within 12 months before baseline visit;

6. A negative transvaginal ultrasound within 6 months before baseline visit.

Exclusion criteria

Diagnosis of ER-negative (<10%) DCIS, or history of invasive breast cancer;
Previous treatment with SERMs or any other hormonal treatment for breast neoplasms;
BMI < 18.5 Kg/m2 and/or Malnutrition Universal Screening Tool (MUST) score ≥2 and/or any current or past eating disorders;
Any diagnosis of invasive neoplasia, except non-melanoma skin cancer, in the previous 5 years;
Any tamoxifen contraindications (abnormal liver function, previous ischemic heart disease, endometrial disorder, previous deep venous thrombosis, history of pulmonary embolus, current or suspected glaucoma, retinopathy and cataract);
Current use of warfarin or other anticoagulant drugs
Bilateral mastectomy;
Pregnancy or desire to become pregnant in the subsequent 9 months after treatment cessation;
Diabetes or any other clinical condition that at the investigator's discretion contraindicates the proposed intervention.
No hormonal contraception is allowed during study intervention. Non-hormonal methods will be advised for women of childbearing potential (WOCBP)

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 4 patient groups, including a placebo group

Low dose tamoxifen

Active Comparator group

Description:

Tamoxifen 10 mg (1 tablet) every other day for 6 months.

Treatment:

Drug: Tamoxifen 10 mg Tablet

Low dose tamoxifen + Intermittent Caloric Restriction

Active Comparator group

Description:

Tamoxifen 10 mg (1 tablet) every other day for 6 months + 5:2 diet (5 days/week at regular energy intake+2 days a week at an average 75% energy deficit)

Treatment:

Other: Intermittent caloric restriction

Drug: Tamoxifen 10 mg Tablet

Lifestyle intervention

Placebo Comparator group

Description:

Step counter device

Treatment:

Behavioral: Step counter Device

Lifestyle Intervention + Intermittent Caloric Restriction

Active Comparator group

Description: